Julius Clinical (Ampersand-backed) Merges with Peachtree BioResearch Solutions

Ampersand Capital Partners Majority Recapitalizes Julius Clinical Research

November 28, 2023

Healthcare Services

Ampersand Capital Partners has completed a majority recapitalization of Julius Clinical Research, a Zeist-based clinical CRO, to support geographic expansion and deepen the company's scientific and therapeutic expertise. The investment will help Julius grow its CRO services in CNS, renal, cardiometabolic and infectious disease areas and expand its footprint in Europe and North America.

P95 Acquires 4Clinics to Expand Global CRO Services

July 1, 2024

Healthcare Services

P95 BV, an Ampersand Capital Partners portfolio company, has acquired 4Clinics, a contract research organization providing data management, biostatistics, medical writing, regulatory affairs and clinical operations. The acquisition (effective July 1, 2024) integrates 4Clinics' team into the P95 group to strengthen CRO capabilities—particularly in biometrics and medical writing—and to enhance service coverage for Francophone clients.

P95 BV (Ampersand-backed) Merges South Africa CRO OnQ Research into P95

October 16, 2023

Healthcare Services

P95 BV, a vaccine-focused CRO and portfolio company of Ampersand Capital Partners, has signed an agreement to merge South Africa-based contract research organization OnQ Research into P95. The deal, structured as an add-on to P95, expands P95's presence across Africa and enhances its vaccine and infectious-disease clinical research and real-world evidence capabilities.

Ampersand Capital Partners Invests in iuvo BioScience

September 28, 2022

Healthcare Services

Ampersand Capital Partners has agreed to acquire a stake in iuvo BioScience, a Rochester-based specialty CRO that provides laboratory, preclinical, clinical development, and scientific consulting services. The investment will fund expansion of iuvo's integrated service portfolio and laboratory capacity and support an active inorganic (add-on) growth strategy; founders Ben Burton and Mary Richardson will remain in leadership roles and as shareholders.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

May 17, 2022

Healthcare Services

Alliance Pharma, an Ampersand-backed US bioanalytical CRO, acquired Drug Development Solutions (DDS), LGC’s UK-based bioanalytical and materials science testing business. Ampersand Capital Partners and KKR will be equal shareholders in the combined business to expand geographic reach, broaden laboratory capabilities, and extend the service portfolio internationally.